A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Fluvastatin (Lescol)

HMG-CoA Reductase Inhibitor (Statin) class · 3 generic manufacturers · 6 ANDAs filed at FDA.

First FDA approval2000-10-06
Generic availableYes · 3 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$10.7M in CY2024 Part D spend59K claims · 20K beneficiaries · 329 plans surveyed

Lowest NADAC
$2.54/unit
15 NDCs benchmarked, lowest of all strengths.
Average NADAC
$3.47
Across all dosage forms in distribution.
Highest NADAC
$13.06
Wide spread — brand-strength NDCs still in market.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Fluvastatin used for?

Fluvastatin is a HMG-CoA Reductase Inhibitor (Statin) medication tracked in Medicare Part D.

Is there a generic for Fluvastatin?

Yes. 6 ANDAs filed at FDA, 3 generic manufacturers currently shipping.

How much does my plan pay for Fluvastatin?

Across 329 Part D plans, Fluvastatin averages $3.47/unit (NADAC). Lowest available: $2.54/unit. Highest in distribution: $13.06/unit.

Is Fluvastatin on the FDA shortage list?

Fluvastatin has been discontinued by its manufacturer(s).

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

HMG-CoA Reductase Inhibitor (Statin)1 alternative in D1
01
Pravastatin
HMG-CoA Reductase Inhibitor (Statin)
$0.060Lowest NADAC
12Generic mfrs
$188.5MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (7 approvals on file) · NADAC unit costs: CMS NADAC weekly file (15 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.